Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target on the stock.

May 08, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reaffirmed a Buy rating on Heron Therapeutics with a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could positively influence Heron Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100